The use of a specific CDK8/CDK19 inhibitor showed supportive results that this effect is dependent on the kinase activity of CDK8 and the same study provides evidence that combination treatments with either anti-programmed death 1 (PD-1) monoclonal antibodies in a colorectal cancer model or SMAC mimetic in a breast cancer model increase the survival of mice [13]. Here, CDK8 is linked to colorectal cancer.